JP2019520328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520328A5 JP2019520328A5 JP2018560588A JP2018560588A JP2019520328A5 JP 2019520328 A5 JP2019520328 A5 JP 2019520328A5 JP 2018560588 A JP2018560588 A JP 2018560588A JP 2018560588 A JP2018560588 A JP 2018560588A JP 2019520328 A5 JP2019520328 A5 JP 2019520328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- tissue
- formula
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 238000002600 positron emission tomography Methods 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338872P | 2016-05-19 | 2016-05-19 | |
| US62/338,872 | 2016-05-19 | ||
| PCT/US2017/033004 WO2017201111A1 (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520328A JP2019520328A (ja) | 2019-07-18 |
| JP2019520328A5 true JP2019520328A5 (enExample) | 2020-06-25 |
| JP6953444B2 JP6953444B2 (ja) | 2021-10-27 |
Family
ID=59021563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560588A Active JP6953444B2 (ja) | 2016-05-19 | 2017-05-17 | Ｐｅｔイメージング用免疫修飾因子 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11103605B2 (enExample) |
| EP (2) | EP3827849A1 (enExample) |
| JP (1) | JP6953444B2 (enExample) |
| KR (1) | KR102378288B1 (enExample) |
| CN (1) | CN109414514B (enExample) |
| AU (1) | AU2017268291B2 (enExample) |
| BR (1) | BR112018073642A2 (enExample) |
| CA (1) | CA3024844A1 (enExample) |
| CY (1) | CY1124241T1 (enExample) |
| DK (1) | DK3458111T3 (enExample) |
| EA (1) | EA038019B1 (enExample) |
| ES (1) | ES2864091T3 (enExample) |
| HR (1) | HRP20210644T8 (enExample) |
| HU (1) | HUE054306T2 (enExample) |
| IL (1) | IL262962B (enExample) |
| LT (1) | LT3458111T (enExample) |
| MA (1) | MA53402A (enExample) |
| MX (1) | MX2018014028A (enExample) |
| PL (1) | PL3458111T3 (enExample) |
| PT (1) | PT3458111T (enExample) |
| RS (1) | RS61742B1 (enExample) |
| SG (1) | SG11201810177VA (enExample) |
| SI (1) | SI3458111T1 (enExample) |
| SM (1) | SMT202100238T1 (enExample) |
| WO (1) | WO2017201111A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US11857352B2 (en) | 2016-09-06 | 2024-01-02 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| RS67792B1 (sr) | 2016-12-01 | 2026-03-31 | Regeneron Pharma | Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje |
| BR112019012986A2 (pt) * | 2016-12-23 | 2019-12-03 | Univ Johns Hopkins | imageamento de tumores e de células imunes com base na expressão de pd-l1 |
| BR112019016336A2 (pt) | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| CN110997698B (zh) | 2017-06-23 | 2023-12-26 | 百时美施贵宝公司 | 充当pd-1拮抗剂的免疫调节剂 |
| CN110997013B (zh) | 2017-07-24 | 2022-09-20 | 瑞泽恩制药公司 | 抗cd8抗体和其用途 |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
| CN110504017B (zh) * | 2019-07-30 | 2022-06-10 | 哈尔滨医科大学 | 一种示踪剂的制备和使用方法 |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| CN114929728A (zh) | 2020-01-06 | 2022-08-19 | 百时美施贵宝公司 | 免疫调节剂 |
| CN115485288A (zh) * | 2020-03-16 | 2022-12-16 | 百时美施贵宝公司 | 免疫调节剂 |
| KR20220161407A (ko) | 2020-03-30 | 2022-12-06 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| US12159403B2 (en) * | 2021-06-18 | 2024-12-03 | The United States Government As Represented By The Department Of Veteran Affairs | Combination of features from biopsies and scans to predict prognosis in SCLC |
| AU2023395853A1 (en) * | 2022-12-12 | 2025-06-19 | Merck Sharp & Dohme Llc | Cyclic peptides as pet imaging agents of granzyme b |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5128119A (en) | 1989-06-12 | 1992-07-07 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of f(ab1)2 fragments |
| US5328679A (en) | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5746996A (en) | 1994-06-03 | 1998-05-05 | Immunomedics, Inc. | Thiolation of peptides for radionuclide-based radiodetection and radiotherapy |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| AU717020B2 (en) | 1996-05-03 | 2000-03-16 | Immunomedics Inc. | Targeted combination immunotherapy of cancer |
| ATE380038T1 (de) | 1996-07-12 | 2007-12-15 | Immunomedics Inc | Radiometall-bindende peptide analoge |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| DE69837095T2 (de) | 1997-09-03 | 2007-11-22 | Immunomedics, Inc. | Fluorierung von proteinen und peptiden für positronemissionstomographie |
| US9090668B2 (en) | 2007-03-26 | 2015-07-28 | The University Of Tokyo | Process for synthesizing cyclic peptide compound |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| JP6206943B2 (ja) | 2010-12-03 | 2017-10-04 | 国立大学法人 東京大学 | ペプチドライブラリーの製造方法、ペプチドライブラリー、及びスクリーニング方法 |
| EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| CN104245726A (zh) | 2012-03-29 | 2014-12-24 | 奥瑞基尼探索技术有限公司 | 来自人pd1的bc环的免疫调节环状化合物 |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| MX355396B (es) | 2012-06-06 | 2018-04-18 | Polyphor Ag | Peptido - mimeticos de la horquilla beta. |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR20150131269A (ko) | 2013-03-15 | 2015-11-24 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| MX2016002970A (es) | 2013-09-06 | 2016-10-07 | Aurigene Discovery Tech Ltd | Compuestos peptidomimeticos ciclicos como inmunomoduladores. |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| MA40132B1 (fr) | 2014-09-11 | 2019-04-30 | Bristol Myers Squibb Co | Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) * | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| JP6622814B2 (ja) * | 2014-11-25 | 2019-12-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | イメージングのための新規ｐｄ−ｌ１結合ポリペプチド |
| WO2016086036A2 (en) | 2014-11-25 | 2016-06-02 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of biologics |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
| KR102526034B1 (ko) | 2016-11-07 | 2023-04-25 | 브리스톨-마이어스 스큅 컴퍼니 | 면역조정제 |
| CN110997698B (zh) | 2017-06-23 | 2023-12-26 | 百时美施贵宝公司 | 充当pd-1拮抗剂的免疫调节剂 |
| EP3692053A1 (en) | 2017-10-03 | 2020-08-12 | Bristol-Myers Squibb Company | Immunomodulators |
-
2017
- 2017-05-17 WO PCT/US2017/033004 patent/WO2017201111A1/en not_active Ceased
- 2017-05-17 EP EP21152813.8A patent/EP3827849A1/en not_active Withdrawn
- 2017-05-17 SG SG11201810177VA patent/SG11201810177VA/en unknown
- 2017-05-17 EP EP17728696.0A patent/EP3458111B1/en active Active
- 2017-05-17 CN CN201780042462.1A patent/CN109414514B/zh active Active
- 2017-05-17 SI SI201730690T patent/SI3458111T1/sl unknown
- 2017-05-17 LT LTEP17728696.0T patent/LT3458111T/lt unknown
- 2017-05-17 US US16/098,765 patent/US11103605B2/en active Active
- 2017-05-17 EA EA201892635A patent/EA038019B1/ru unknown
- 2017-05-17 AU AU2017268291A patent/AU2017268291B2/en active Active
- 2017-05-17 KR KR1020187036396A patent/KR102378288B1/ko active Active
- 2017-05-17 CA CA3024844A patent/CA3024844A1/en active Pending
- 2017-05-17 DK DK17728696.0T patent/DK3458111T3/da active
- 2017-05-17 PL PL17728696T patent/PL3458111T3/pl unknown
- 2017-05-17 SM SM20210238T patent/SMT202100238T1/it unknown
- 2017-05-17 MX MX2018014028A patent/MX2018014028A/es unknown
- 2017-05-17 PT PT177286960T patent/PT3458111T/pt unknown
- 2017-05-17 JP JP2018560588A patent/JP6953444B2/ja active Active
- 2017-05-17 BR BR112018073642-2A patent/BR112018073642A2/pt not_active Application Discontinuation
- 2017-05-17 HU HUE17728696A patent/HUE054306T2/hu unknown
- 2017-05-17 MA MA053402A patent/MA53402A/fr unknown
- 2017-05-17 ES ES17728696T patent/ES2864091T3/es active Active
- 2017-05-17 HR HRP20210644TT patent/HRP20210644T8/hr unknown
- 2017-05-17 RS RS20210499A patent/RS61742B1/sr unknown
-
2018
- 2018-11-12 IL IL262962A patent/IL262962B/en active IP Right Grant
-
2021
- 2021-04-29 CY CY20211100375T patent/CY1124241T1/el unknown
- 2021-08-26 US US17/412,612 patent/US20210386876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brody et al. | Chemokine receptor 2–targeted molecular imaging in pulmonary fibrosis. A clinical trial | |
| Seo et al. | Technological development and advances in single-photon emission computed tomography/computed tomography | |
| JP2022508699A5 (enExample) | ||
| Hoh et al. | Positron emission tomography in urological oncology | |
| Tatsumi et al. | Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose | |
| JP2019527225A5 (enExample) | ||
| EP3634499A1 (en) | Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans | |
| Wall et al. | Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT | |
| JP2022016473A (ja) | 肝臓及び／又は腎臓機能の診断剤 | |
| Puri et al. | [18F] Fluoromisonidazole PET in rectal cancer | |
| Estorch et al. | Future challenges of multimodality imaging | |
| Fularz et al. | Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level | |
| Molnar et al. | Impact of PET/CT imaging with FDG in locally advanced cervical carcinoma—a literature review | |
| JP2018502829A5 (enExample) | ||
| Cheng et al. | Evaluation of bone remodeling with 18F-fluoride and correlation with the glucose metabolism measured by 18F-FDG in lumbar spine with time in an experimental nude rat model with osteoporosis using dynamic PET-CT | |
| Yagi et al. | High-throughput multiple-mouse imaging with micro-PET/CT for whole-skeleton assessment | |
| Suzuki-Shibata et al. | Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy | |
| US11266755B2 (en) | Development and application of tumor diagnostic radioactive probe targeting folic acid receptor | |
| Hansen et al. | Pulmonary langerhans cell histiocytosis: PET/CT for initial workup and treatment response evaluation | |
| RU2405569C2 (ru) | Способ визуализации "сторожевых" лимфоузлов при раке гортани и гортаноглотки | |
| Yoo et al. | Monitoring of macrophage accumulation in statin-treated atherosclerotic mouse model using sodium iodide symporter imaging system | |
| Wang et al. | High-resolution dynamic imaging and quantitative analysis of lung cancer xenografts in nude mice using clinical PET/CT | |
| Schöder et al. | PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer | |
| Dunphy et al. | Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging | |
| JP2022508692A (ja) | 転移性前立腺がんを処置するための併用療法 |